Hosted by NantKwest (NASDAQ: NK) and ImmunityBio
The call will feature a moderated discussion with NantKwest and ImmunityBio Chairman and Chief Executive Officer Patrick Soon-Shiong, MBBCh, MSS, FRCS (C) covering the Companies’ strategic initiatives in developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS). The call will be moderated by LifeSci Advisors followed by a Q&A session at the conclusion of the call.
NantKwest and ImmunityBio, both within the NantWorks family of companies, are leveraging their expertise in off-the-shelf, cell-based therapies, and vaccine development, natural killer cell activation, and immunomodulators, respectively, to combat COVID-19. The following topics will be covered on the call:
- Vaccine Vector to Protect Against SARS-CoV-2 Infection with ImmunityBio’s second-generation human adenovirus platform (hAd5)
- Therapeutic Immunomodulators for Patients with Mild-to-Moderate COVID-19 Symptoms leveraging NantKwest’s haNK CD16 off-the-shell natural-killer cells and ImmunityBio’s IL-15 superagonist, N-803
- Therapeutic for Severe and Critically Ill COVID-19 Patients on Ventilator Support with NantKwest’s bone marrow-derived mesenchymal stem cells (MSC) to mitigate ‘cytopathic storm’
DATE: May 27 2020
TIME 12:00 pm (EST)